Jobs and Innovation
Pharmaceutical Technology Europe
The middle word in our magazine's title is technology, so I cannot fail to join the increasing numbers of people in all fields of business commenting on the passing of Steve Jobs.
The middle word in our magazine's title is technology, so I cannot fail to join the increasing numbers of people in all fields of business commenting on the passing of Steve Jobs. I, like many, many others, discovered the news on one of the devices he was so proud of. Personally, I was surprised at how moved I was by the flood of tributes paid to Steve Jobs in the days following his death. I think it was the true scope of how many people all over the world have been affected by the decisions he made. The innovation and ability to pre-empt people's future needs shown by Steve Jobs and his team at Apple have changed even the way we do business; a real inspiration.
Rich Whitworth
Ever since the iPad was launched, there have been news stories about pharma companies investing in iPads for its sales force, or for scientists to use in its laboratories. And certainly Pharmaceutical Technology Europe will be making use of the new media at our disposal in the coming months. But perhaps the pharma industry would do well to look at Apple's business model and game-changing strategies to make more significant changes.
You would think working for Apple and job satisfaction go hand in hand... This month, PharmTech.com is running its annual employment survey, which gives you a chance to let us know what's happening in your sector and how you feel about it. We will be publishing the results in our December issue as well as online, but this can only happen if you take part! So, please go to PharmTech.com/survey2011 where you will be led through questions ranging from the affect of the current economic climate to the reasons you want to leave, or stay at, your current job. There is also a store gift card (not Apple!) up for grabs, if you need even more convincing.
Best wishes,
Rich Whitworth
Navigating Annex 1 for Early Phase Sterile Fill Finish in Clinical Supplies
November 21st 2024Stay compliant with Annex 1 for early phase sterile fill finish processes. Discover how to implement robust contamination control strategies, integrate isolator technology, and conduct integrity testing to meet stringent European Union standards. The guide provides a comprehensive look at key elements such as PUPSIT, critical zone controls, and monitoring and training for aseptic processes.
Why is the PDA Pharmaceutical Microbiology Conference the Hottest Ticket in the Industry?
October 10th 2024Get a glimpse of the power and popularity behind the PDA Pharmaceutical Microbiology Conference from two planning committee members, Julia Marre, PhD (Associate Director, Scientific and Regulatory Affairs at Pocket Naloxone Corp) and Dawn Watson (Executive Director, Global Micro Quality and Sterility Assurance at Merck). This candid conversation reveals why this industry event is so influential…and always sold out! The speakers discuss what makes the PDA Pharmaceutical Microbiology Conference so vital to industry professionals, as well as how to become a part of this dynamic professional community.
Ensuring Quality from the Start: Raw Materials Testing Support
November 21st 2024Raw Materials are the foundation of every biopharma product. Our ultimate guide highlights how our testing support can help you establish purity, identity, and quality standards, ensuring a smooth manufacturing process and adherence to regulatory requirements.
Ensure the Safety of Allogeneic Therapies with Advanced qPCR Testing
November 21st 2024Elevate your viral screening with Eurofins BioPharma Product Testing’s qPCR- based assays. Our advanced testing goes beyond standard screenings to detect even dormant and hard-to-detect pathogens, ensuring comprehensive safety in every stage of the allogeneic therapy pipeline. Protect your products – and your patients- with industry-leading sensitivity and specificity.
